J Thromb Haemost: Growth differentiation factor-15 can be used to predict bleeding events in cancer patients

Growth differentiation factor 15 (GDF-15) in patients with atrial fibrillation is a strong predictor of bleeding, but not with respect to the biomarker in cancer patients cardiac vascular data outcomes

Recently, a research article was published in the Journal of Thrombosis and Haemostasis, an authoritative journal of thrombosis and coagulation diseases, which aims to evaluate the efficacy of GDF-15 as a predictor of bleeding events in cancer patients

In this trial, 574 participants were randomly assigned to the prophylactic apixaban treatment group or the placebo group, and were followed up for 180 days for venous thromboembolism, major bleeding, clinically relevant non-major bleeding, and any bleeding

Among those receiving apixaban, the area under the subject-operating characteristic curve of GDF-15 predicting major bleeding was 0.

This shows that this study shows that GDF-15 can predict bleeding events in cancer patients receiving thromboprophylaxis